Bristol reviews Plavix ad
Executive Summary
Bristol-Myers Squibb has conducted an audit of a recent Plavix direct-to-consumer ad and maintains that there is no difference in the speed of delivery between efficacy and safety/risk information in voiceovers. At a recent Regulatory Affairs Professional Society DTC conference, a Bristol regulatory director agreed with attendees that the voice delivering the safety information was faster (1"The Pink Sheet" May 22, 2006, p. 27). Attendees also said the change from a male voice to a female voice for delivery of the safety/risk information was distracting. Bristol said it intentionally switched voices to call attention to safety/risk information and noted that the ad was pre-cleared by FDA...
You may also be interested in...
DTC Guideline Implementation: Does “Ask Your Doctor” Spark A Dialogue?
As industry continues to implement PhRMA's guidelines on direct-to-consumer ads, debate has arisen as to how companies can effectively enact the principle that advertising should encourage a conversation between patient and physician
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.